These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 27542246)
1. Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer. Wolfson E; Goldenberg M; Solomon S; Frishberg A; Pinkas-Kramarski R Oncotarget; 2016 Oct; 7(40):65320-65334. PubMed ID: 27542246 [TBL] [Abstract][Full Text] [Related]
2. Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer. Wolfson E; Solomon S; Schmukler E; Goldshmit Y; Pinkas-Kramarski R Cell Death Dis; 2018 Jan; 9(2):47. PubMed ID: 29352243 [TBL] [Abstract][Full Text] [Related]
3. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination. Fonseca NA; Rodrigues AS; Rodrigues-Santos P; Alves V; Gregório AC; Valério-Fernandes Â; Gomes-da-Silva LC; Rosa MS; Moura V; Ramalho-Santos J; Simões S; Moreira JN Biomaterials; 2015 Nov; 69():76-88. PubMed ID: 26283155 [TBL] [Abstract][Full Text] [Related]
4. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Xia W; Bacus S; Hegde P; Husain I; Strum J; Liu L; Paulazzo G; Lyass L; Trusk P; Hill J; Harris J; Spector NL Proc Natl Acad Sci U S A; 2006 May; 103(20):7795-800. PubMed ID: 16682622 [TBL] [Abstract][Full Text] [Related]
5. ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression. Qi L; Zhang B; Zhang S; Ci X; Wu Q; Ma G; Luo A; Fu L; King JL; Nahta R; Dong JT Oncotarget; 2017 May; 8(22):36054-36066. PubMed ID: 28415602 [TBL] [Abstract][Full Text] [Related]
6. Copine-III interacts with ErbB2 and promotes tumor cell migration. Heinrich C; Keller C; Boulay A; Vecchi M; Bianchi M; Sack R; Lienhard S; Duss S; Hofsteenge J; Hynes NE Oncogene; 2010 Mar; 29(11):1598-610. PubMed ID: 20010870 [TBL] [Abstract][Full Text] [Related]
7. Differential regulation of ErbB2 expression by cAMP-dependent protein kinase in tamoxifen-resistant breast cancer cells. Yang JW; Kim MR; Kim HG; Kim SK; Jeong HG; Kang KW Arch Pharm Res; 2008 Mar; 31(3):350-6. PubMed ID: 18409049 [TBL] [Abstract][Full Text] [Related]
8. Flotillin depletion affects ErbB protein levels in different human breast cancer cells. Asp N; Pust S; Sandvig K Biochim Biophys Acta; 2014 Sep; 1843(9):1987-96. PubMed ID: 24747692 [TBL] [Abstract][Full Text] [Related]
9. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth. Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873 [TBL] [Abstract][Full Text] [Related]
10. MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance. Paulson AK; Linklater ES; Berghuis BD; App CA; Oostendorp LD; Paulson JE; Pettinga JE; Melnik MK; Vande Woude GF; Graveel CR Mol Cancer Res; 2013 Sep; 11(9):1112-21. PubMed ID: 23825050 [TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904 [TBL] [Abstract][Full Text] [Related]
12. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2. Karakashev SV; Reginato MJ Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742 [TBL] [Abstract][Full Text] [Related]
13. DEPTOR stabilizes ErbB2 to promote the proliferation and survival of ErbB2-positive breast cancer cells. Bi Y; Chen X; Wei B; Wang L; Gong L; Li H; Xiong X; Zhao Y Theranostics; 2021; 11(13):6355-6369. PubMed ID: 33995662 [No Abstract] [Full Text] [Related]
14. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer. Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235 [TBL] [Abstract][Full Text] [Related]
15. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Chen FL; Xia W; Spector NL Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964 [TBL] [Abstract][Full Text] [Related]
16. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells. Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492 [TBL] [Abstract][Full Text] [Related]
17. ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth. Hermanto U; Zong CS; Wang LH Oncogene; 2001 Nov; 20(51):7551-62. PubMed ID: 11709727 [TBL] [Abstract][Full Text] [Related]
19. Transfer-RNA-mediated enhancement of ribosomal proteins S6 kinases signaling for cell proliferation. Kwon NH; Lee MR; Kong J; Park SK; Hwang BJ; Kim BG; Lee ES; Moon HG; Kim S RNA Biol; 2018; 15(4-5):635-648. PubMed ID: 28816616 [TBL] [Abstract][Full Text] [Related]
20. Interfering with the interaction between ErbB1, nucleolin and Ras as a potential treatment for glioblastoma. Goldshmit Y; Trangle SS; Kloog Y; Pinkas-Kramarski R Oncotarget; 2014 Sep; 5(18):8602-13. PubMed ID: 25261371 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]